Affiliation:
1. A. M. Granov Russian Research Center of Radiology and Surgical Technologies
Abstract
A review of the literature on the current capabilities of radioisotope imaging of prostate cancer is presented. Various views and experience of using PET/CT for visualization of prostate cancer are considered. Particular attention is paid to the use of various radiopharmaceuticals used in staging, restaging prostate cancer, as well as monitoring the response to treatment. The advantages and disadvantages of most radiotracers used to search for disease recurrence are highlighted, as well as the peculiarities of their use in various clinical situations. The features of the effect of hormonal therapy for prostate cancer on imaging are discussed.
Publisher
Non-profit partnership Society of Interventional Oncoradiologists
Reference92 articles.
1. Каприн АД, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2016 г.: заболеваемость и смертность. МНИОИ им. П.А. Герцена Минздрава России. 2018. 18 с.
2. Moyer VA. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-34. DOI: 10.7326/0003-4819157-2201207170-00459.PMID: 22801674.
3. Pushkar DY, Govorov AV, Sidorenkov AV, et al. Early diagnosis of prostate cancer. Methodical recommendations № 19. Moscow. 2015:8-9. (In Russian).
4. Nosov DA, Volkova MI, Gladkov OA, et al. Practical recommendations for drug treatment of prostate cancer. Malignant tumors: Practical guidelines RUSSCO # 3s2, 2019;9:519-32 (In Russian).
5. Hricak H, White S, Vigneron D, et al. Cancer of the prostate gland: MR imaging with pelvic-phased-array coils versus integrated endorectal-pelvic phased – array coils. Radiology. 1994;193:703-9.